Literature DB >> 24467627

Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection.

Benjamin J Staudinger1, Jocelyn Fraga Muller, Skarphéðinn Halldórsson, Blaise Boles, Angus Angermeyer, Dao Nguyen, Henry Rosen, Olafur Baldursson, Magnús Gottfreðsson, Guðmundur Hrafn Guðmundsson, Pradeep K Singh.   

Abstract

RATIONALE: Progress has been made in understanding how the cystic fibrosis (CF) basic defect produces lung infection susceptibility. However, it remains unclear why CF exclusively leads to chronic infections that are noninvasive and highly resistant to eradication. Although biofilm formation has been suggested as a mechanism, recent work raises questions about the role of biofilms in CF.
OBJECTIVES: To learn how airway conditions attributed to CF transmembrane regulator dysfunction could lead to chronic infection, and to determine if biofilm-inhibiting genetic adaptations that are common in CF isolates affect the capacity of Pseudomonas aeruginosa to develop chronic infection phenotypes.
METHODS: We studied P. aeruginosa isolates grown in agar and mucus gels containing sputum from patients with CF and measured their susceptibility to killing by antibiotics and host defenses. We also measured the invasive virulence of P. aeruginosa grown in sputum gels using airway epithelial cells and a murine infection model.
MEASUREMENTS AND MAIN RESULTS: We found that conditions likely to result from increased mucus density, hyperinflammation, and defective bacterial killing could all cause P. aeruginosa to grow in bacterial aggregates. Aggregated growth markedly increased the resistance of bacteria to killing by host defenses and antibiotics, and reduced their invasiveness. In addition, we found that biofilm-inhibiting mutations do not impede aggregate formation in gel growth environments.
CONCLUSIONS: Our findings suggest that conditions associated with several CF pathogenesis hypotheses could cause the noninvasive and resistant infection phenotype, independently of the bacterial functions needed for biofilm formation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24467627      PMCID: PMC4225830          DOI: 10.1164/rccm.201312-2142OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  73 in total

1.  A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms.

Authors:  Hirotoshi Matsui; Victoria E Wagner; David B Hill; Ute E Schwab; Troy D Rogers; Brian Button; Russell M Taylor; Richard Superfine; Michael Rubinstein; Barbara H Iglewski; Richard C Boucher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

2.  Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  Baoleri Lee; Janus A J Haagensen; Oana Ciofu; Jens Bo Andersen; Niels Høiby; Søren Molin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.

Authors:  Eric E Smith; Danielle G Buckley; Zaining Wu; Channakhone Saenphimmachak; Lucas R Hoffman; David A D'Argenio; Samuel I Miller; Bonnie W Ramsey; David P Speert; Samuel M Moskowitz; Jane L Burns; Rajinder Kaul; Maynard V Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-10       Impact factor: 11.205

4.  Iron and Pseudomonas aeruginosa biofilm formation.

Authors:  Ehud Banin; Michael L Vasil; E Peter Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-25       Impact factor: 11.205

5.  Neutrophil elastase, an innate immunity effector molecule, represses flagellin transcription in Pseudomonas aeruginosa.

Authors:  Avinash Sonawane; Jeevan Jyot; Russell During; Reuben Ramphal
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

6.  CFTR regulates phagosome acidification in macrophages and alters bactericidal activity.

Authors:  Anke Di; Mary E Brown; Ludmila V Deriy; Chunying Li; Frances L Szeto; Yimei Chen; Ping Huang; Jiankun Tong; Anjaparavanda P Naren; Vytautas Bindokas; H Clive Palfrey; Deborah J Nelson
Journal:  Nat Cell Biol       Date:  2006-08-20       Impact factor: 28.824

Review 7.  Congenital immunodeficiencies and sepsis.

Authors:  Jordan S Orange
Journal:  Pediatr Crit Care Med       Date:  2005-05       Impact factor: 3.624

8.  Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung.

Authors:  Dinesh D Sriramulu; Heinrich Lünsdorf; Joseph S Lam; Ute Römling
Journal:  J Med Microbiol       Date:  2005-07       Impact factor: 2.472

9.  Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology.

Authors:  Kelli L Palmer; Lauren M Mashburn; Pradeep K Singh; Marvin Whiteley
Journal:  J Bacteriol       Date:  2005-08       Impact factor: 3.490

10.  Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease.

Authors:  H Matsui; B R Grubb; R Tarran; S H Randell; J T Gatzy; C W Davis; R C Boucher
Journal:  Cell       Date:  1998-12-23       Impact factor: 41.582

View more
  59 in total

Review 1.  The Interaction between Respiratory Pathogens and Mucus.

Authors:  Mark Zanin; Pradyumna Baviskar; Robert Webster; Richard Webby
Journal:  Cell Host Microbe       Date:  2016-02-10       Impact factor: 21.023

Review 2.  Biofilms 2018: A diversity of microbes and mechanisms.

Authors:  Clay Fuqua; Alain Filloux; Jean-Marc Ghigo; Karen L Visick
Journal:  J Bacteriol       Date:  2019-02-19       Impact factor: 3.490

Review 3.  Hyperinflammation and airway surface liquid dehydration in cystic fibrosis: purinergic system as therapeutic target.

Authors:  Thiago Inácio Teixeira do Carmo; Victor Emanuel Miranda Soares; Jonatha Wruck; Fernanda Dos Anjos; Débora Tavares de Resende E Silva; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini
Journal:  Inflamm Res       Date:  2021-04-27       Impact factor: 4.575

4.  Genome-Wide Survey of Pseudomonas aeruginosa PA14 Reveals a Role for the Glyoxylate Pathway and Extracellular Proteases in the Utilization of Mucin.

Authors:  Jeffrey M Flynn; Chi Phan; Ryan C Hunter
Journal:  Infect Immun       Date:  2017-07-19       Impact factor: 3.441

5.  Visualizing the Effects of Sputum on Biofilm Development Using a Chambered Coverglass Model.

Authors:  Trevor Beaudoin; Sarah Kennedy; Yvonne Yau; Valerie Waters
Journal:  J Vis Exp       Date:  2016-12-14       Impact factor: 1.355

6.  Cystic fibrosis transmembrane conductance regulator and pseudomonas.

Authors:  Edith T Zemanick; Frank J Accurso
Journal:  Am J Respir Crit Care Med       Date:  2014-04-01       Impact factor: 21.405

Review 7.  Microbial Biofilms in Pulmonary and Critical Care Diseases.

Authors:  Andree-Anne Boisvert; Matthew P Cheng; Don C Sheppard; Dao Nguyen
Journal:  Ann Am Thorac Soc       Date:  2016-09

8.  Paraoxonase 2 serves a proapopotic function in mouse and human cells in response to the Pseudomonas aeruginosa quorum-sensing molecule N-(3-Oxododecanoyl)-homoserine lactone.

Authors:  Christian Schwarzer; Zhu Fu; Takeshi Morita; Aaron G Whitt; Aaron M Neely; Chi Li; Terry E Machen
Journal:  J Biol Chem       Date:  2015-01-27       Impact factor: 5.157

9.  Entropically driven aggregation of bacteria by host polymers promotes antibiotic tolerance in Pseudomonas aeruginosa.

Authors:  Patrick R Secor; Lia A Michaels; Anina Ratjen; Laura K Jennings; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-01       Impact factor: 11.205

10.  Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes.

Authors:  Nicole Mayer-Hamblett; Margaret Rosenfeld; Ronald L Gibson; Bonnie W Ramsey; Hemantha D Kulasekara; George Z Retsch-Bogart; Wayne Morgan; Daniel J Wolter; Christopher E Pope; Laura S Houston; Bridget R Kulasekara; Umer Khan; Jane L Burns; Samuel I Miller; Lucas R Hoffman
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.